CVPA (37710-81-9) is an aquaporin-1 inhibitor (IC50 = 8.1 μM) discovered by molecular docking against the extracellular domain of human aquaporin-1 followed by experimental testing in a Xenopus oocyte swelling assay.1
TC AQP1 1 is a human aquaoporin-1 (hAQP1) selective inhibitor and is considered to have therapeutic potential towards the potential treatment of glaucoma, brain edema, inflammatory pain and certain types of cancer.
1) Seeliger et al. (2012), Discovery of novel human aquaporin-1 blockers; ACS Chem. Biol., 8 249